Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Varsha Gandhi, PhD, on Ibrutinib

May

Today In Oncology

Colorectal Cancer Incidence Is Rising Among Teenagers and Young Adults

Lymphoid Neoplasms European National Health Expenditure and Long-Term Survival

Doublet for Previously Treated Patients With Advanced Leiomyosarcoma

Survey Finds Majority of Patients With Cancer and Survivors Have or Expect to Incur Medical Debt—Even Those With Insurance

Oral Rinse Could Provide Early Screening for Gastric Cancer

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Varsha Gandhi, PhD, on Ibrutinib

Colorectal Cancer Incidence Is Rising Among Teenagers and Young Adults

Lymphoid Neoplasms European National Health Expenditure and Long-Term Survival

Doublet for Previously Treated Patients With Advanced Leiomyosarcoma

Survey Finds Majority of Patients With Cancer and Survivors Have or Expect to Incur Medical Debt—Even Those With Insurance

Oral Rinse Could Provide Early Screening for Gastric Cancer